Final EMA scientific advice for pivotal Phase III vitiligo
Filed with ASX · · 3 pages · English
Summary by 6ix AI
Clinuvel Pharmaceuticals Limited has received final scientific advice from the European Medicines Agency regarding its pivotal Phase III study for vitiligo treatment using SCENESSE®. The EMA emphasized a 'totality of evidence' approach for evaluating the drug's efficacy, which will include patient-reported outcomes and clinical data from previous studies. This announcement marks a significant step forward in Clinuvel's efforts to develop a systemic treatment for vitiligo, particularly for patients with darker skin tones.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Clinuvel Pharmaceuticals' latest callClinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings Call · Replay · Aug 27Read the transcript of Clinuvel Pharmaceuticals (ASX:CUV) Q4 2026 Earnings CallClinuvel Pharmaceuticals Limited on 6ix
Earlier from Clinuvel Pharmaceuticals
- CLINUVEL's global programs showcased at AAD
- Chair Letter to Shareholders
- Half Year Results Presentation
- CLINUVEL Record Revenues, Advances Strategic Expansion
- Appendix 4D and Half Year Report
Later from Clinuvel Pharmaceuticals
- CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study
- FDA relaxes SCENESSE postmarketing requirement
- CLINUVEL update on Level II ADR upgrade, Nasdaq uplist
- CLINUVEL publicly files 20-F to U.S. SEC
- SCENESSE approved for EPP in Canada
Follow Clinuvel Pharmaceuticals into a list and get an email when it puts out news.
Follow Clinuvel Pharmaceuticals